Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer

被引：1

作者：

Kikuchi, Eiji ^{[1
]}

Hayakawa, Nozomi ^{[1
]}

机构：

[1] St Marianna Univ, Dept Urol, Sch Med, Kawasaki, Kanagawa 2168511, Japan

来源：

LANCET ONCOLOGY | 2020年 / 21卷 / 08期

关键词：

D O I：

10.1016/S1470-2045(20)30236-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1005 / 1006

页数：2

共 50 条

[21] Single-arm phase II study of low-dose paclitaxel and pembrolizumab in platinum-refractory metastatic urothelial carcinoma (UC).
Bitting, Rhonda L.
Vile, Donald Charles
Tooze, Janet A.
Thomas, Christopher Y.
Neve, Morgan
Kooshki, Mitra
Brown, Jessica
Dubey, Purnima
Triozzi, Pierre
Goodman, Michael Moses
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[22] Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Shilpa Gupta
Ashish M. Kamat
Nature Reviews Urology, 2020, 17 : 540 - 540
[23] Paclitaxel plus cetuximab vs. nivolumab for patients with platinum-refractory recurrent/metastatic head and neck cancer
Kodama, Hiroyuki
Kadowaki, Shigenori
Wakabayashi, Munehiro
Nakata, Akinobu
Kumanishi, Ryosuke
Nakazawa, Taeko
Ogata, Takatsugu
Matsubara, Yuki
Honda, Kazunori
Masuishi, Toshiki
Narita, Yukiya
Tanigichi, Hiroya
Ando, Masashi
Hanai, Nobuhiro
Muro, Kei
ANNALS OF ONCOLOGY, 2023, 34 : S1388 - S1388
[24] Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival
Nakamori, Keita
Yamazaki, Shogo
Komura, Kazumasa
Fukuokaya, Wataru
Adachi, Takahiro
Hirasawa, Yosuke
Hashimoto, Takeshi
Yoshizawa, Atsuhiko
Ohno, Takaya
Yano, Yusuke
Nishimura, Kazuki
Tokushige, Satoshi
Uchimoto, Taizo
Yamamoto, Shutaro
Iwatani, Kosuke
Urabe, Fumihiko
Mori, Keiichiro
Yanagisawa, Takafumi
Tsuduki, Shunsuke
Takahara, Kiyoshi
Inamoto, Teruo
Miki, Jun
Kimura, Takahiro
Ohno, Yoshio
Shiroki, Ryoichi
Azuma, Haruhito
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2023, 39
[25] A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer
Wilailak, S
Linasmita, V
ONCOLOGY, 2004, 67 (3-4) : 183 - 186
[26] Radiomic biomarkers for platinum-refractory head and neck cancer in the era of immunotherapy
Lu, Hsueh-Ju
Shen, Chao-Yu
Chiu, Yu-Wei
Lin, Wea-Lung
Peng, Chih-Yu
Tseng, Hsien-Chun
Hsin, Chung-Han
Chuang, Chun-Yi
Chen, Chun-Chia
Wu, Ming-Fang
Huang, Wei-Shiou
Shen, Wei-Chih
ORAL DISEASES, 2024,
[27] EFFICACY OF MULTILINE CHEMOTHERAPY FOR PLATINUM-REFRACTORY OR - RESISTANT RECURRENT OVARIAN CANCER
Iwase, H.
Ono, S.
Takada, T.
Arai, T.
Arai, M.
Onda, T.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 194 - 194
[28] Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Okada, Takuro
Matsuki, Takashi
Fushimi, Chihiro
Okamoto, Isaku
Sato, Hiroki
Kondo, Takahito
Tokashiki, Kunihiko
Ito, Tatsuya
Masubuchi, Tatsuo
Tada, Yuichiro
Miura, Kouki
Hanyu, Kenji
Omura, Go
Takahashi, Hideki
Yamashita, Taku
Oridate, Nobuhiko
Tsukahara, Kiyoaki
ANTICANCER RESEARCH, 2022, 42 (10) : 4907 - 4912
[29] Pembrolizumab Versus Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer
Takemura, Ayana
Matsushita, Yuto
Tamura, Keita
Sugiyama, Takayuki
Nagata, Masao
Otsuka, Atsushi
Miyake, Hideaki
IN VIVO, 2021, 35 (03): : 1889 - 1894
[30] Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
Bitting, Rhonda L.
Tooze, Janet A.
Goodman, Michael
Vile, Donald C.
Brown, Jessica M.
Thomas, Christopher Y.
Neve, Morgan
Kooshki, Mitra
Addo, Safoa
Triozzi, Pierre L.
Dubey, Purnima
CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 530 - 539

← 1 2 3 4 5 →